Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Phase 3

Active, not recruiting

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: LOU064 (blinded)
Drug: Placebo
Drug: LOU064 (open label)

First Posted Date: 2022-08-23

Last Posted Date: 2024-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 698

Registration Number: NCT05513001

Locations: 🇺🇸
The Clinical Research Center, Saint Louis, Missouri, United States
🇺🇸
Somnos Clinical Research, Lincoln, Nebraska, United States
🇺🇸
Orion Clinical Research, Austin, Texas, United States

and more 42 locations

Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury

Phase 2

Completed

Conditions: Acute Kidney Injury Due to Sepsis

Interventions: Biological: TIN816 70 mg lyophilisate powder
Other: Placebo

First Posted Date: 2022-08-19

Last Posted Date: 2024-05-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT05507437

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Spain

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

Phase 2

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: LTP001
Drug: Standard of Care (SoC)

First Posted Date: 2022-08-11

Last Posted Date: 2024-10-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT05497284

Locations: 🇺🇸
University of Kansas Hospital Main Centre, Kansas City, Kansas, United States
🇺🇸
University of Alabama at Birmingham ., Birmingham, Alabama, United States
🇵🇱
Novartis Investigative Site, Bialystok, Poland

Characteristics of Patients With Sickle Cell Disease

Completed

Conditions: Sickle Cell Disease

Interventions: Other: Crizanlizumab

First Posted Date: 2022-08-10

Last Posted Date: 2022-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 540

Registration Number: NCT05494541

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Phase 1

Withdrawn

Conditions: Hepatic Impairment

Interventions: Drug: TNO155

First Posted Date: 2022-08-05

Last Posted Date: 2024-02-29

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05490030

Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Midostaurin

First Posted Date: 2022-08-04

Last Posted Date: 2022-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 81

Registration Number: NCT05488613

Locations: 🇫🇮
Novartis Investigative Site, Helsinki, Finland

Study Conducted Among Patients With CML

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Other: Tyrosine Kinase Inhibitors (TKIs)

First Posted Date: 2022-07-27

Last Posted Date: 2022-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3234

Registration Number: NCT05476562

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Phase 1

Active, not recruiting

Conditions: Mild Cognitive Impairment
Alzheimer Disease

Interventions: Drug: NIO752
Drug: Matching placebo

First Posted Date: 2022-07-21

Last Posted Date: 2024-11-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT05469360

Locations: 🇸🇪
Novartis Investigative Site, Stockholm, Sweden

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck
Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Esophageal Squamous Cell Carcinoma

Interventions: Biological: QEQ278

First Posted Date: 2022-07-18

Last Posted Date: 2024-11-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT05462873

Locations: 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Massachusetts General Hospital Dept. of Mass General Hospital, Boston, Massachusetts, United States

and more 1 locations

A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

Phase 2

Active, not recruiting

Conditions: Osteoarthritis, Knee

Interventions: Drug: QUC398
Drug: Placebo

First Posted Date: 2022-07-18

Last Posted Date: 2024-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 101

Registration Number: NCT05462990

Locations: 🇺🇸
Clinical Research of West Florida Inc ., Tampa, Florida, United States
🇺🇸
Boston Univ School Of Medicine Biomed Research, Boston, Massachusetts, United States
🇺🇸
West Clinical Research Private Clinic, Morehead City, North Carolina, United States

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy